A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer — PROFILE 1001  

Systemic Anaplastic Large-Cell Lymphoma Clinical Trial

Official title: PHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER

Status Completed

Clinical Trial Summary

PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. This research study is the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth daily.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Advanced Malignancies Except Leukemia
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Lymphoma, Large-Cell, Anaplastic
• Non-Small Cell Lung Cancer ALK-positive
• Non-Small Cell Lung Cancer c-Met Dependent
• Non-Small Cell Lung Cancer ROS Marker Positive
• Systemic Anaplastic Large-Cell Lymphoma

• NCT number: NCT00585195
• Study type: Interventional
• Source: Pfizer
• Status: Completed
• Phase: Phase 1
• Start date: April 19, 2006
• Completion date: January 19, 2022